TL;DR
Get baking supplies delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Food Safety News publisher says he has filed two citizen petitions asking the FDA to disclose more information in food outbreak investigations, including company identities and locations. His argument draws on the agency’s stated commitment to “radical transparency,” but the supplied report excerpt does not include the petitions’ full requests or the FDA’s response to them.
Food Safety News publisher Bill Marler says he is asking the FDA, through two citizen petitions, to disclose more information about foodborne illness outbreaks, including company and location details. In a publisher’s column published in October 2026, Marler argues the requests align with the agency’s own stated commitment to “radical transparency”; the available report excerpt does not set out the petitions in full or give the FDA’s response.
Marler frames the petitions as a request to complete information already partly provided in FDA summaries of closed outbreak investigations, echoing calls for greater transparency. The agency began publishing Executive Incident Summary abstracts in September 2025. Marler credits that step but says summaries can leave out details the public needs to identify where an outbreak occurred and which companies may be involved.
He cites examples of the information gap, a concern also raised in coverage of an outbreak with an unnamed supplier. According to the column, FDA did not name a company in its summary of a mango outbreak, and a separate summary concerning a fatal Listeria outbreak redacted details including patients’ states of residence. Marler also says FDA closed a romaine-related E. coli investigation in September without identifying a grower, processor or brand. These are examples presented by the column; the supplied material does not include the underlying summaries or FDA’s explanations for each redaction.
The column also describes a 50-person E. coli O157:H7 outbreak linked to chicken wraps, an issue related to public identification of companies in E. coli outbreaks. Marler says the public learned the brand through a lawsuit and a newspaper rather than an FDA or USDA Food Safety and Inspection Service announcement, and says FSIS later confirmed the source to a reporter. He discloses that he represents plaintiffs in that outbreak. The source text ends while discussing FDA’s October 28 announcement that the investigation was over, so it does not provide the rest of his account of that case.
What Outbreak Summaries Leave Out
Outbreak summaries can help people understand whether a food hazard has been identified and whether an investigation has ended. If company names and locations are withheld, consumers may have less information to assess whether a product they bought could be involved. The same details can matter to retailers, health professionals, investigators and businesses working to trace potentially contaminated food.
The petitions also raise a question about how agencies balance public disclosure with legal limits on releasing commercial information. Marler argues that naming companies should be part of food-safety transparency. That is his position, not a finding that the FDA is legally required to release every name or detail in every investigation. The public-interest case for disclosure must be considered alongside the agency’s stated legal concerns and the specifics of each outbreak.
Products Worth Considering

Vitamix Ascent X2 SmartPrep Kitchen System, Black

Breville Barista Express Espresso Machine with Built-In Grinder, Black Truffle

KitchenAid KSMPRA 3-Piece Pasta Roller and Cutter Set
As an affiliate, we earn on qualifying purchases.
FDA’s Transparency Commitments
The column traces the administration’s use of “radical transparency” to Health and Human Services Secretary Robert F. Kennedy Jr. In January 2025 confirmation testimony, Kennedy promised transparency and said, “We should tell Americans when we don’t know.” In a February address to HHS staff, he linked transparency to informed consent. The phrases are quoted in Marler’s account.
In March 2025, HHS and FDA connected the phrase to food in a statement about reviewing the self-affirmed GRAS pathway. FDA later used it in a July letter to food industry leaders about recall communications, saying transparency in food-safety and nutrition actions was key to reducing foodborne illness and chronic disease. In September, the agency described the new outbreak abstracts as part of that commitment.
Marler says a separate citizen petition from Stop Foodborne Illness, submitted in February, asked FDA to stop treating company names as confidential. He reports that the agency cited the Trade Secrets Act in its answer. He argues that the legal issue has since been answered, but the excerpt does not identify the development he relies on or supply a ruling, legal analysis or full text of either new petition. FDA leadership has also changed: the column says former commissioner Marty Makary resigned in May 2026 and that food-program deputy commissioner Kyle Diamantas became acting commissioner. It reports that President Donald Trump nominated Heidi Overton in August 2026.
Petition Details and FDA Response
The supplied report excerpt does not include the full text of the two petitions, their filing dates, the exact records or disclosure rules they seek, or any response from FDA. It also does not identify the legal development Marler says resolves the Trade Secrets Act question. The scope of any applicable legal authority, and whether it would require or permit disclosure in particular outbreak cases, therefore cannot be established from this material.
It is also unclear from the excerpt what FDA said when it closed the chicken-wrap investigation on October 28, 2026. Marler’s description of the outbreak includes his representation of plaintiffs, a relevant disclosure for readers weighing his account. The source provides no FDA comment on his petitions or on the specific examples of withheld details.
FDA’s Decision on the Petitions
The next concrete development is whether FDA accepts, rejects or otherwise responds to the two citizen petitions. The supplied material gives no deadline or expected decision date. A response could clarify the agency’s view of its authority to name companies and locations in outbreak summaries, as well as any limits it believes apply.
Until the petitions and an agency response are available, readers should distinguish Marler’s request and examples from settled policy or legal conclusions. Further reporting would need the petition texts, FDA’s formal answers and the records behind the outbreak summaries cited in the column.
Key Questions
What is Bill Marler asking the FDA to do?
Marler says two citizen petitions ask FDA to disclose more identifying information in food outbreak investigations, including company and location details. The supplied report excerpt does not give the petitions’ full wording.
Has the FDA agreed to disclose company names?
The source material does not report an FDA decision on Marler’s petitions. It says FDA previously cited the Trade Secrets Act when responding to a separate petition about company names.
What outbreak information does Marler say is missing?
He points to summaries that, according to his column, omit company identities or locations. His examples include summaries involving mango, Listeria and romaine, as well as a chicken-wrap E. coli outbreak.
Why does the request matter to consumers?
More detailed public summaries could help consumers judge whether a product or location may be relevant to an outbreak. Whether FDA can or should disclose particular details remains subject to the agency’s legal assessment and the facts of each investigation.
Source: foodsafetynews.com
